SPOTLIGHT -
Matthew Krebs, MB, PhD, Reviews the Next Steps for Subcutaneous Amivantamab in Solid Tumors
Matthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.
Matthew Krebs, MB, PhD Discusses Phase 1 PALOMA Trial Results of Subcutaneous Amivantamab in Solid Tumors
Matthew Krebs, MB, PhD spoke about efficacy of subcutaneous amivantamab observed in the phase 1 PALOMA trial for patients with solid tumors.
Matthew Krebs, MB, PhD, Talks Rationale for the PALOMA Trial of Subcutaneous Amivantamab in Solid Tumors
Matthew Krebs, MB, PhD spoke about the reasoning for the phase 1 PALOMA trial in patients with solid tumors who received a subcutaneous formulation of amivantamab.
